肿瘤细胞治疗研究
英文原题：CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors.
克服肿瘤微环境的物理屏障仍是嵌合抗原受体（CAR）T 细胞疗法治疗实体瘤的主要障碍。
克服肿瘤微环境的物理屏障仍是CAR-T细胞疗法治疗实体瘤的主要障碍。本期Van Pelt及其同事的研究显示，对靶向GD2的CAR-T细胞进行工程化改造，使其表达基质金属蛋白酶7和增强型骨桥蛋白，可提高其浸润富含细胞外基质肿瘤的能力。这些改造在临床前模型中增强了功能，且未增加脱靶毒性。研究结果凸显了一种有前景策略：设计具有细胞外基质重塑能力的CAR-T细胞。相关论文见Van Pelt等，第1732页。
Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. 1732.
MEMBER ACCOUNT
登录成功会直接打开下一页。
